Evaluating disease severity in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 26, Issue 145, 2017, Pages

  Robbie, Hasti ^a   Daccord, Cécile ^a,b   Chua, Felix ^a   Devaraj, Anand ^c  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; MORTALITY RISK; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; QUANTITATIVE STUDY; REVIEW; SIX MINUTE WALK TEST; STAGING; BIOPSY; DIAGNOSTIC IMAGING; FIBROSING ALVEOLITIS; LUNG; LUNG FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; X-RAY COMPUTED TOMOGRAPHY;

BIOPSY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85019915825     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0051-2017     Document Type: Review

References (98)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
3. Rudd RM, Prescott RJ, Chalmers JC, et al. British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007; 62: 62-66.
4. King TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001; 164: 1025-1032.
5. Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-2217.
6. Flaherty K, Toews G, Travis W, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19: 275-283.
7. Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
8. Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology 2014; 273: 570-579.
9. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiological index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969.
10. Satoh H, Kurishima K, Ishikawa H, et al. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006; 260: 429-434.
11. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135: 1557-1563.
12. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 717-723.
13. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
14. Sokai A, Handa T, Tanizawa K, et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res 2015; 16: 120.
15. Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015; 3: 462-472.
16. Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011; 12: 143.
17. Saketkoo LA, Mittoo S, Huscher D, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2013; 69: 436-444.
18. Lammi MR, Baughman RP, Birring SS, et al. Outcome measures for clinical trials in interstitial lung diseases. Curr Respir Med Rev 2015; 11: 163-174.
19. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
20. Papiris SA, Daniil ZD, Malagari K, et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005; 99: 755-761.
21. Khadawardi H, Mura M. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology 2016; 22: 501-507.
22. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-975.
23. Van Manen MJG, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev 2016; 25: 278-286.
24. Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough 2010; 6: 4.
25. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
26. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
27. American Thoracic Society and European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
28. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
29. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-835.
30. Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 989-997.
31. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
32. Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung 2016; 194: 739-743.
33. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620-628.
34. King TE, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis: implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189: 825-831.
35. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2016; 5: 33-41.
36. Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71: 429-435.
37. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017; 72: 340-346.
38. Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 2016; 48: 843-851.
39. Sverzellati N, Guerci L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J 2011; 38: 392-400.
40. Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med 2016; 194: 1445-1446.
41. King TE, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-177.
42. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-537.
43. Taylor Gonzalez A, Maher T. Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort. Eur Respir J 2016; 48: suppl 60, OA282.
44. Corte TJ, Wort SJ, MacDonald PS, et al. Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology 2012; 17: 674-680.
45. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
46. Goldin JG, Hansell DM, Goldin JG, et al. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir 2015; 3: 483-496.
47. Du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 1421-1429.
48. Nathan SD, Du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med 2015; 109: 914-922.
49. Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
50. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171: 1150-1157.
51. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174: 803-809.
52. Swigris JJ, Swick J, Wamboldt FS, et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009; 136: 841-848.
53. Swigris JJ, Olson AL, Shlobin OA, et al. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16: 439-445.
54. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 711-718.
55. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
56. Wells AU, Rubens MB, du Bois RM, et al. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol 1993; 161: 1159-1165.
57. Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148: 1076-1082.
58. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 172: 488-493.
59. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.
60. Jeong YJ, Lee KS, Müller NL, et al. Usual interstitial pneumonia and non-specific interstitial pneumonia: serial thin-section CT findings correlated with pulmonary function. Korean J Radiol 2005; 6: 143-152.
61. Edey AJ, Devaraj AA, Barker RP, et al. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011; 21: 1586-1593.
62. Yamauchi H, Bando M, Baba T, et al. Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing. PLoS ONE 2016; 11: e0166168.
63. Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2016; 195: 1-34.
64. Shin KM, Lee KS, Chung MP, et al. Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study. Radiology 2008; 249: 328-337.
65. Romei C, Tavanti L, Sbragia P, et al. Idiopathic interstitial pneumonias: do HRCT criteria established by ATS/ ERS/JRS/ALAT in 2011 predict disease progression and prognosis? Radiol Medica 2015; 120: 930-940.
66. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia. Am J Respir Crit Care Med 2008; 177: 433-439.
67. Lee HY, Lee KS, Jeong YJ, et al. High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implications. Am J Roentgenol 2012; 199: 982-989.
68. Hwang J-H, Misumi S, Curran-Everett D, et al. Longitudinal follow-up of fibrosing interstitial pneumonia: relationship between physiologic testing, computed tomography changes, and survival rate. J Thorac Imaging 2011; 26: 209-217.
69. Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res 2014; 15: 10.
70. Hartley PG, Galvin JR, Hunninghake GW, et al. High-resolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol 1994; 76: 271-277.
71. Best AC, Lynch AM, Bozic CM, et al. Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology 2003; 228: 407-414.
72. Sverzellati N, Calabrò E, Chetta A, et al. Visual score and quantitative CT indices in pulmonary fibrosis: relationship with physiologic impairment. Radiol Medica 2007; 112: 1160-1172.
73. Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 204-212.
74. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging 2016; 31: 304-311.
75. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of automated computer tomographic analysis with conventional severity measures. Eur Respir J 2017; 49: pii: 1601011.
76. Salisbury ML, Lynch DA, van Beek EJR, et al. Idiopathic pulmonary fibrosis: the association between the adaptive multiple features method and fibrosis outcomes. Am J Respir Crit Care Med 2017; 195: 921-929.
77. Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013; 266: 936-944.
78. Nusair S, Rubinstein R, Freedman NM, et al. Positron emission tomography in interstitial lung disease. Respirology 2007; 12: 843-847.
79. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 2009; 50: 538-545.
80. Meissner H-H, Soo Hoo GW, Khonsary SA, et al. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 2006; 73: 197-202.
81. 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging 2009; 36: 1121-1130.
82. 18F-FDG PET for idiopathic pulmonary fibrosis. J Nucl Med 2015; 56: 1869-1875.
83. King MA, Bergin CJ, Ghadishah E, et al. Detecting pulmonary abnormalities on magnetic resonance images in patients with usual interstitial pneumonitis: effect of varying window settings and gadopentetate dimeglumine. Acad Radiol 1996; 3: 300-307.
84. Rea G. Magnetic resonance imaging in the evaluation of idiopathic pulmonary fibrosis: a real possibility, or an attractive challenge? Quant Imaging Med Surg 2016; 6: 331-333.
85. Yi CA, Lee KS, Han J, et al. 3-T MRI for differentiating inflammation- and fibrosis-predominant lesions of usual and nonspecific interstitial pneumonia: comparison study with pathologic correlation. Am J Roentgenol 2008; 190: 878-885.
86. Lavelle LP, Brady D, McEvoy S, et al. Pulmonary fibrosis: tissue characterization using late-enhanced MRI compared with unenhanced anatomic high-resolution CT. Diagnostic Interv Radiol 2017; 23: 106-111.
87. Mirsadraee S, Tse M, Kershaw L, et al. T1 characteristics of interstitial pulmonary fibrosis on 3T MRI-a predictor of early interstitial change? Quant Imaging Med Surg 2016; 6: 42-49.
88. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-695.
89. Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000 Res 2016; 5: 1-13.
90. Ley B, Bradford WZ, Weycker D, et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1374-1381.
91. Salisbury ML, Xia M, Zhou Y, et al. Idiopathic pulmonary fibrosis: gender-age-physiology index stage for predicting future lung function decline. Chest 2016; 149: 491-498.
92. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220-224.
93. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164: 1722-1727.
94. Wolters P, Collard H, Jones K. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157-179.
95. Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 173-177.
96. Walsh SLF, Wells AU, Sverzellati N, et al. Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med 2015; 13: 241.
97. Wells AU. “Any fool can make a rule and any fool will mind it”. BMC Med 2016; 14: 23.
98. Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500-505.